EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudie

Antibiotic Tolerability in Nocardia Infection Among Kidney Transplant Recipients: A Multicenter Cohort Study

M Pérez-Mir iD, C Canal Girol, L Escolà-Vergé, S Codina Sánchez, B O Chamoun, Z Castañeda, A Gonzalez Rojas, Ángela Isabel Casas Parra, Marc Gordo, Guillem López de Egea Vegas, Cristina Pitart, Adrià Antuori und 5 weitere

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70239 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von M Pérez-Mir und 16 weiteren Autor:innen. Beteiligte Einrichtung: Transplant Nephrology Unit, Department of Nephrology, Fundació Puigvert, Barcelona, Spain. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Kidney Transplantation, Nocardia Infections. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Departments of Nephrology and Microbiology of the participating centers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nocardia infection is a rare but severe complication in kidney transplant (KT) recipients, with high morbidity and mortality. Data on antibiotic tolerability in this population are scarce.

Methods

We conducted a retrospective, multicentric study across six Spanish transplant units to analyze clinical characteristics, treatment strategies, and antibiotic tolerability in KT patients diagnosed with Nocardia infection.

Results

Twenty‐six cases of Nocardia infection were identified, predominantly in elderly male patients with significant comorbidities and a high immunosuppressive burden. Pulmonary involvement was the most common presentation, although extrapulmonary manifestations also occurred. Only 36% of infections occurred within the first posttransplant year. Most patients received initial combination therapy, followed by prolonged treatment—primarily with trimethoprim–sulfamethoxazole (TMP‐SMX) or linezolid. However, antibiotic tolerability was poor: TMP‐SMX was discontinued in 80% of cases due to adverse effects, mainly hyperkalemia, metabolic acidosis, and acute kidney injury. Linezolid was withdrawn in 90% of patients because of myelotoxicity. Tedizolid, used in 38.4% of cases, showed better tolerability, with only 20% of treatment discontinuation and no relapses reported during follow‐up. Overall, mortality during treatment reached 30.8%, mainly due to infectious causes.

Conclusions

This is the largest series of Nocardia infection in KT recipients in Spain and the first to specifically evaluate antibiotic tolerability. TMP‐SMX and linezolid were poorly tolerated, reinforcing the need for alternative strategies. Tedizolid showed a favorable safety profile and may be considered a promising first‐line option in high‐risk patients. Further prospective studies are needed to confirm these findings and support guideline development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsKidney TransplantationNocardia InfectionsAdultAgedFemaleHumansMaleMiddle AgedLinezolidNocardiaRetrospective StudiesSpainTransplant RecipientsTrimethoprim, Sulfamethoxazole Drug Combination

Stichwörter der Autor:innen

antibiotic tolerabilitykidney transplantationnocardiosisopportunistic infectionssolid organ transplant recipientstedizolidtrimethoprim–sulfamethoxazole

Substanzen

Anti-Bacterial AgentsLinezolidTrimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Transplant Nephrology Unit, Department of Nephrology, Fundació Puigvert, Barcelona, Spain.
  • Department of Infectious Diseases; Department of Medicine, Hospital de la Santa Creu i Sant Pau; Universitat Autònoma de Barcelona, Institut D'investigació Biomèdica Sant Pau, Barcelona, Spain.
  • CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
  • Transplant Nephrology Unit, Department of Nephrology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain.
  • Transplant Nephrology Unit, Department of Nephrology, Hospital Del Mar, Barcelona, Spain.
  • Transplant Nephrology Unit, Department of Nephrology, Vall d'Hebron University Hospital, Barcelona, Spain.

ORCID-Profile: M Pérez-Mir

Förderung

  • Departments of Nephrology and Microbiology of the participating centers

Zitieren

APA

Pérez-Mir, M., Canal Girol, C., Escolà-Vergé, L., Codina Sánchez, S., Chamoun, B. O., Castañeda, Z., Gonzalez Rojas, A., Casas Parra, Á. I., Gordo, M., López de Egea Vegas, G., Pitart, C., Antuori, A., Guirado, L., Fayos De Arizon, L., Serra Cabañas, N., Cordoba Herrera, C., & Facundo Molas, C. (2026). Antibiotic Tolerability in Nocardia Infection Among Kidney Transplant Recipients: A Multicenter Cohort Study. Transplant Infectious Disease. https://doi.org/10.1111/tid.70239

Vancouver

Pérez-Mir M, Canal Girol C, Escolà-Vergé L, Codina Sánchez S, Chamoun BO, Castañeda Z, et al. Antibiotic Tolerability in Nocardia Infection Among Kidney Transplant Recipients: A Multicenter Cohort Study. Transplant Infectious Disease. 2026. doi:10.1111/tid.70239

BibTeX
@article{PrezMir2026,
  author = {Pérez-Mir, M and Canal Girol, C and Escolà-Vergé, L and Codina Sánchez, S and Chamoun, B O and Castañeda, Z and Gonzalez Rojas, A and Casas Parra, Ángela Isabel and Gordo, Marc and López de Egea Vegas, Guillem and Pitart, Cristina and Antuori, Adrià and Guirado, Lluís and Fayos De Arizon, Leonor and Serra Cabañas, Núria and Cordoba Herrera, Christian and Facundo Molas, Carme},
  title = {Antibiotic Tolerability in Nocardia Infection Among Kidney Transplant Recipients: A Multicenter Cohort Study},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70239}
}
Kostenlos starten →